Published in Nephrol Dial Transplant on January 01, 1992
Prediction of resources needed to achieve the national target for treatment of renal failure. Br Med J (Clin Res Ed) (1987) 4.65
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine (2000) 3.22
Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax (2004) 2.45
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int (2001) 1.99
Incidence of advanced chronic renal failure and the need for end stage renal replacement treatment. BMJ (1990) 1.83
Squamous cell carcinoma of bronchus presenting with Henoch-Schönlein purpura. Br Med J (1978) 1.78
IgM associated primary diffuse mesangial proliferative glomerulonephritis. J Clin Pathol (1980) 1.75
Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol (1989) 1.63
A flexible model for planning facilities for patients with end-stage renal failure. Br Med J (1980) 1.57
Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant (1992) 1.53
Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet (1979) 1.50
The need and demand for renal replacement therapy in ethnic minorities in England. J Epidemiol Community Health (1996) 1.47
Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) (1998) 1.46
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant (1996) 1.39
Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings. Br J Ophthalmol (1989) 1.24
Disseminated herpes simplex virus infection with hepatitis in an adult renal transplant recipient. J Clin Pathol (1981) 1.21
Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet (1968) 1.17
Observations on calcium metabolism in the nephrotic syndrome. Q J Med (1967) 1.17
Should patients with renal failure associated with myeloma be dialysed? Br Med J (Clin Res Ed) (1983) 1.17
Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol (2000) 1.16
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology (2001) 1.15
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol (1999) 1.14
The importance of urinary immunoglobulin light chain isoelectric point (pI) in nephrotoxicity in multiple myeloma. Clin Sci (Lond) (1984) 1.11
Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int (1999) 1.11
Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine (1998) 1.10
The treatment of lupus nephritis by methyl prednisolone pulse therapy. Postgrad Med J (1978) 1.07
Properdin factor B alleles in patients with idiopathic membranous nephropathy. Tissue Antigens (1980) 1.07
Public attitudes towards kidney transplantation. Br Med J (1976) 1.06
Diseases and histological normality of the renal glomerulus: a clinicopathological study. J Clin Pathol (1976) 1.05
Glomerular basement membrane proteoglycans are derived from a large precursor. J Cell Biol (1988) 1.04
Dialysis in the management of the renal failure of myeloma. Q J Med (1989) 1.04
Liver transplantation in man after an extended period of preservation by a simple technique. Br Med J (1969) 1.02
Cell-mediated immunity in nephrotic syndrome. Lancet (1972) 1.00
Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol (2001) 1.00
Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br J Ophthalmol (2008) 0.99
Rapid screening for the hepatitis-associated antigen prior to human renal transplantation. Lancet (1970) 0.98
Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int (1986) 0.98
Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy. N Engl J Med (1984) 0.98
The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations. Clin Exp Immunol (1980) 0.96
Report on management of renal failure in children in Europe, XXIII, 1992. Nephrol Dial Transplant (1994) 0.96
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol (1999) 0.95
Clinical membranous nephropathy. Nephron (1983) 0.95
Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet (1987) 0.94
Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet (1969) 0.94
Gm allotypes in membranous nephropathy. N Engl J Med (1983) 0.94
Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol (2000) 0.94
Elective Hypothermic Cardiac Arrest in Normothermic Animals. Ann Surg (1961) 0.93
IgM-associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators. Q J Med (1991) 0.92
Abnormal urinary rhythm after renal transplantation in man. Lancet (1968) 0.92
Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant (1994) 0.91
Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int (1995) 0.91
A soluble glucose polymer for use in renal failure and calorie-deprivation states. Lancet (1969) 0.91
An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol (1998) 0.90
Evidence for cell-mediated immunity to renal antigens in minimal-change nephrotic syndrome. Lancet (1976) 0.90
Letter: Acute-on-chronic renal failure precipitated by clofibrate. Lancet (1976) 0.90
Cerebral damage from declotting Scribner shunts. Lancet (1969) 0.90
Bartter's syndrome--observations on the pathophysiology. Q J Med (1982) 0.89
The pathogenesis of minimal change nephropathy. Clin Nephrol (1977) 0.88
Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis (1994) 0.88
A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation (1995) 0.88
Human herpesvirus 6 infection in renal-transplant recipients. N Engl J Med (1989) 0.87
Immune potential in human uraemia. 1. Relationship of glomerular filtration rate to depression of immune potential. J Clin Pathol (1976) 0.87
A peroxidase-linked enzyme immunoassay for tumour necrosis factor alpha utilising alternative colorimetric or chemilumimetric substrates. J Immunol Methods (1992) 0.86
Evidence that matching for HLA antigens significantly increases transplant survival in 1001 renal transplants performed in the northwest region of England. Transplantation (1989) 0.86
Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome. Nephron (1996) 0.86
Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant (1995) 0.85
Early cytokine response to multiple injury. Injury (1993) 0.85
Peritoneal dialysis. Lancet (1999) 0.85
Value of tissue-typing in cadaveric renal transplantation. Lancet (1971) 0.85
Inherited plasma factor deficiency in haemolytic-uraemic syndrome. Lancet (1981) 0.85
Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients. Nephrol Dial Transplant (2001) 0.84
The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth. J Clin Periodontol (2000) 0.84
Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus. J Clin Periodontol (2000) 0.84
Transforming growth factor beta 1 in renal allograft recipients. Transplantation (1994) 0.84
Urinary N-acetyl-beta-D-glucosaminidase as an indicator of tubular damage in multiple myeloma. Clin Chim Acta (1984) 0.84
Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation (1987) 0.84
Autoimmunity in IgA nephropathy. Lancet (1988) 0.84
The changing pattern of children's dialysis and transplantation over 20 years. Clin Nephrol (1994) 0.83
Serum and urine IL-6 and TNF-alpha in renal transplant recipients with graft dysfunction. Transplantation (1993) 0.83
The nephrotic syndrome and ischaemic heart disease. Nephron (1981) 0.83
Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate. Biochem J (1989) 0.83
Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron (1997) 0.83
Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int (1992) 0.83
A study of the renin-angiotensin system in the nephrotic syndrome. Nephron (1974) 0.83